Navigation Links
Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Date:8/27/2007

TORONTO, Aug. 27 /PRNewswire/ -- Drug Royalty LP 2 (DRC) announced today the purchase of 25% of Enzon Pharmaceuticals, Inc.'s (ENZN) worldwide royalty interest in PEG-INTRON for $92.5M. DRC will also provide a $15M milestone payment in 2012 should certain royalty recognition levels be met. PEG-INTRON (peginterferon alpha-2b), is approved for the treatment of Hepatitis C and is marketed worldwide by Schering-Plough Corporation (SGP).

Speaking on behalf of DRC, Paul Kirkconnell, Managing Director, said: "DRC is very pleased to be working with Enzon Pharmaceuticals. We believe that PEG- INTRON is one of the most advanced medications to treat Hepatitis C on the market today." Kirkconnell added, "With access to significant capital and a long track record in completing royalty transactions, we take pride in meeting the needs of pharmaceutical companies such as Enzon."

About PEG-INTRON(R)

PEG-INTRON is a PEG-enhanced version of Schering-Plough's alpha interferon product, INTRON(R) A, which is used both as a monotherapy and in combination with REBETOL(R) (ribavirin) capsules for the treatment of chronic hepatitis C. Under Enzon's license agreement with Schering-Plough, Schering-Plough holds an exclusive worldwide license to PEG-INTRON, and Enzon receives royalties on worldwide sales of PEG-INTRON. Schering-Plough is responsible for all manufacturing, marketing, and development activities for PEG-INTRON. Enzon designed PEG-INTRON to allow for less frequent dosing and to yield greater efficacy, as compared to INTRON A. PEG-INTRON is marketed worldwide by Schering-Plough and its affiliates.

About Drug Royalty Corporation, Inc. (DRC)

Drug Royalty Corporation ("DRC") is a privately held investment management company, focused on the healthcare industry, with over $1 billion under management. DRC currently manages two funds: the Royalty Monetization Fund and the Structured Finance Fund.

Its Royalty Monetization Fund acquires existing roya
'/>"/>

SOURCE Drug Royalty Corporation, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Trouble-shooting: Misincorporation or low fidelity
2. Roche Diagnostics Corporation
3. Roche Diagnostics Corporation
4. Promega Corporation: Wisconsins quiet innovator
5. Giuliani will keynote RedPrairie Corporations user conference
6. Madison Development Corporation makes loans to three area companies
7. Corporations and blogging
8. Metavante acquires Florida banking corporation
9. TriMas Corporations Cequent Group Acquires Chem-Chrome, Inc.
10. Speaker announces business members of IT Task Force
11. Doyle announces technology tax credits for Berbee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... in the development of quantum technologies has been proposed ... published today (28 October) in Nature Communications , ... a new type of flexibly designed microscopic trap for ... and specialised superfast computers, often depend on harnessing the ... these tiny particles are hugely problematic because of the ...
(Date:10/27/2014)... The new research report, “Gas Insulated Switchgear (GIS) ... & Secondary), and End-User (Transmission & Distribution, Manufacturing ... - Trends and Forecasts to 2019”, defines and ... of the market size. , Browse more than ... through 146 Pages and in-depth TOC on “Gas ...
(Date:10/27/2014)... 2014 Kalorama Information says that PCR is ... the United States and is ... researcher said the FDA,s Emergency Use Authorization (EUA) to authorize ... the detection of the Ebola virus was an indication ... assess the IVD industry and its biennial survey on ...
(Date:10/27/2014)... (PRWEB) October 27, 2014 Called ... reducing and eliminating several types of pediatric brain ... been achieved in over 30 years of research ... Light Foundation, proves that one mom's determination can ... just before Halloween trick-or-treating, and it’s only fitting ...
Breaking Biology Technology:Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 3Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 4Kalorama: PCR The Go-to Test in Ebola Fight 2Kalorama: PCR The Go-to Test in Ebola Fight 3FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 2FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 3
... ATLANTA, Aug. 27 Alimera Sciences, Inc., today announced that ... which was originally completed in March 2008. In connection with this ... received warrants for an additional $10 million in Series C preferred stock. ... delivery of Phase III top-line data for Iluvien(R) to elect to exercise ...
... , , BOSTON, Aug. 27 The Center ... to announce their full agenda for the 3rd Annual ... Over 60 firms are already confirmed to gather in Philadelphia on ... discuss industry case examples for accounting for collaborations and transactions. Perspectives ...
... ... (a licensed manufacturer of clinical grade biological products as licensed by the State of California ... two of its latest scientific discoveries at the 2009 World Stem Cell Summit. , ... San Diego, CA (PRWEB) Aug 27, ...
Cached Biology Technology:Alimera Sciences Closes $5 Million in Extended Series C Financing 2Over 60 Firms Confirmed to Attend CBI's Third Annual Bio/Pharmaceutical Collaboration and Transaction Accounting Conference in September 2Stemedica Selected By World Stem Cell Summit To Present Scientific Discoveries 2Stemedica Selected By World Stem Cell Summit To Present Scientific Discoveries 3Stemedica Selected By World Stem Cell Summit To Present Scientific Discoveries 4
(Date:10/30/2014)... 30, 2014—Oligonucleotide-based therapeutics present unique challenges when it ... and developmental harm. New consensus guidelines for toxicity ... and biological characteristics of these novel biopharmaceuticals are ... peer-reviewed journal from Mary Ann Liebert, Inc. ... the Nucleic Acid Therapeutics website until ...
(Date:10/30/2014)... New York | Heidelberg, 30 October 2014 Biological ... a better understanding of adsorption of solution ions ... biological cells. Now, a new study provides a ... and surrounding solution ions. Joanna Kotyńska and Zbigniew ... the authors of a study describing these findings, ...
(Date:10/29/2014)... who lose their hair as a consequence of chemotherapy ... improve the scalp cooling technology that prevents hair loss. ... being pioneered by global scalp cooling manufacturing company, Paxman ... biology department of the University of Huddersfield. , The ... who has a background in the pharmacology of cancer ...
Breaking Biology News(10 mins):New guidelines for reproductive & developmental toxicity testing of oligonucleotide drugs 2Ion adsorption matter in biology 2New technology on the way to aid cancer suffers who lose their hair after chemotherapy 2
... Pharmaceuticals report this week that they have successfully used RNA ... mice, an advance that could lead to new treatments for ... 1998 discovery of RNA interference the naturally occurring phenomenon ... nucleus to the protein-building machinery of the cell is disrupted ...
... New Delhi, Singapore and Washington DC (Dec 28, 2010) ... identify with political parties , according to an article in ... official journal of the Western Political Science Association (published by ... studied concepts in modern political science. Scholars have long held ...
... spotlight that illuminates an otherwise dark scene, attention brings to ... A new study by researchers at the Salk Institute for ... that primarily had been known for its role in the ... the mind,s spotlight. Their findings, published in the Dec. ...
Cached Biology News:New RNA interference technique can silence up to 5 genes 2Seeing without looking 2
... deparaffinize and perform Heat Induced Antigen Retrieval ... mounted on glass microscope slides. Deparffinization is ... high temperature used in HIER (over 90degrees ... by detergent. Formaldehyde fixation impairs or totally ...
... designed to deparaffinize and perform Heat Induced ... tissue sections mounted on glass microscope slides. ... at the high temperature used in HIER ... the paraffin by detergent. Formaldehyde fixation impairs ...
...
...
Biology Products: